Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 42,127	$ 34,264
General and administrative	25,704	19,239
Acquired in-process research and development	15,199
Total operating expenses	83,030	53,503
Loss from operations	(83,030)	(53,503)
Other income (expense):
Interest and investment income	10,201	1,724
Other expense, net	(62)	(55)
Total other income, net	10,139	1,669
Net loss	$ (72,891)	$ (51,834)
Net loss per share attributable to common shareholders - basic	$ (2.42)	$ (3.55)
Net loss per share attributable to common shareholders - diluted	$ (2.42)	$ (3.55)
Weighted-average common shares outstanding used in net loss per share - basic	30,123,316	14,620,618
Weighted-average common shares outstanding used in net loss per share - diluted	30,123,316	14,620,618